

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/814,701	03/30/2004	Lawrence M. Blatt	6319-4502US	7220
29858 7590 01/29/2008 THELEN REID BROWN RAYSMAN & STEINER LLP PO BOX 1510			EXAMINER	
			MOSHER, MARY	
NEW YORK,	NY 10150-1510		ART UNIT	PAPER NUMBER
			1648	
				·
	•		MAIL DATE	DELIVERY MODE
		•	01/29/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/814,701	BLATT, LAWRENCE M.				
Office Action Summary	Examiner	Art Unit				
	Mary E. Mosher, Ph.D.	1648				
The MAILING DATE of this communication a	ppears on the cover sheet with the	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perioder and the provision of the	DATE OF THIS COMMUNICATIO 1.136(a). In no event, however, may a reply be tile of will apply and will expire SIX (6) MONTHS from ute, cause the application to become ABANDONE	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).				
Status	·					
1) Responsive to communication(s) filed on 28	September 2007.					
	-					
3) Since this application is in condition for allow	·					
closed in accordance with the practice under	r <i>Εχ paπe Quayle</i> , 1935 C.D. 11, 4	.53 O.G. 213.				
Disposition of Claims						
4)	rawn from consideration.					
Application Papers						
9) The specification is objected to by the Exami 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction. 11) The oath or declaration is objected to by the	ccepted or b) objected to by the he drawing(s) be held in abeyance. Se ection is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a life section.	ents have been received. ents have been received in Applica riority documents have been receive eau (PCT Rule 17.2(a)).	tion No ved in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892)	4)					
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal 6) Other:					

10/814,701 Art Unit: 1648

DETAILED ACTION

Claim Rejections - 35 USC § 112

Claims 14-16, 20-23, 25-28 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement, for reasons of record. Applicant argues that the examiner must provide references or explain the reasons for doubting the objective truth of applicant's statements, and that the inconclusive studies cited are not inconsistent with applicant's assertions. The previous Office action pointed to the unpredictability of the art of physiology and medicine, and the absence of working examples of the claimed treatment method. "When a patent applicant chooses to forego exemplification and bases utility on broad terminology and general allegations, he runs the risk that unless one with ordinary skill in the art would accept the allegations as obviously valid and correct, the examiner may, properly, ask for evidence to substantiate them. " Ex parte Sudilovsky, 21 USPQ2d 1702, 1705. One skilled in the art of medicine would not have accepted the allegations as obviously valid and correct, considering the contemporary absence of knowledge of the effectiveness of clinical interventions (except the limited effectiveness of steroids) on SARS. Although later in vitro studies did show that interferon had an antiviral effect on SARS infection in culture, the medical art does not accept that tissue culture assays reliably predict efficacy in treating or preventing disease in an individual. The limited clinical data available to date do not substantiate applicant's assertions that IFN- α or IFN α + γ are effective in treating or preventing or reducing the risk of SARS; therefore it is maintained that more than

Application/Control Number:

10/814,701

Art Unit: 1648

routine experimentation would be would be required to practice the claimed body-treating methods.

Double Patenting

Claims 20-23, 25-28 remain provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-13 of copending Application No. 10/552020, for reasons of record. This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented. Applicant did not argue this rejection; applicant's intention to file a terminal disclaimer upon agreement of allowable claims, is noted.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary E. Mosher, Ph.D. whose telephone number is 571-

10/814,701

Art Unit: 1648

Page 4

272-0906. The examiner can normally be reached on varying dates and times; please leave a message..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Mary E Mosher, Ph.D.

Primary Examiner

Art Unit 1648

1/25/08